Atezolizumab, an IgG1 antibody against PD-L1, is suitable for patients with metastatic NSCLC expressing EGFR or ALK mutations, administered during or after platinum-based chemotherapy (Lindeman et al., 2013; Ramos-Esquivel et al., 2017; Siddiqui and Siddiqui, 2023). This evidence concerns the gene EGFR and non-small cell lung carcinoma.